期刊
BIOTECHNIQUES
卷 48, 期 3, 页码 197-209出版社
FUTURE SCI LTD
DOI: 10.2144/000113382
关键词
antibody; validation; immunohistochemistry; immunofluorescence
资金
- National Institutes of Health [CA139431, CA 114277, CA 110511, CA 106709]
- Susan G. Komen Foundation [KG090562]
- Department of Defense [1W81XWH-06-1-0746, 1W81XWH-08-1-0404, 1W81XWH-08-1-0784]
- NATIONAL CANCER INSTITUTE [R01CA114277, R01CA139431, R33CA106709, R33CA110511] Funding Source: NIH RePORTER
Antibodies are among the most frequently used tools in basic science research and in clinical assays, but there are no universally accepted guidelines or standardized methods for determining the validity of these reagents. Furthermore, for commercially available antibodies, it is clear that what is on the label does not necessarily correspond to what is in the tube. To validate an antibody, it must be shown to be specific, selective, and reproducible in the context for which it is to be used. In this review, we highlight the common pitfalls when working with antibodies, common practices for validating antibodies, and levels of commercial antibody validation for seven vendors. Finally, we share our algorithm for antibody validation for immunohistochemistry and quantitative immunofluorescence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据